TMS Co

TMS Co R&D Expenses

The Research & Development Expenses of TMS Co (4891.T) as of Nov 3, 2026 is 548.04 M JPY. In the previous year, Research & Development Expenses was 621.10 M JPY — a change of -11.76% (lower).

R&D Expenses

548.04 MJPY

YoY

-11.76%

Last updated:

Research & Development Expenses of TMS Co is 2026 548.04 M JPY. Research & Development Expenses of TMS Co was 2025 621.10 M JPY. It decreases by -11.76% lower compared to the previous year.

The TMS Co R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2021
603.24 M JPY
Jan 1, 2022
103.11 M JPY
Jan 1, 2023
292.76 M JPY
Jan 1, 2024
607.73 M JPY
Jan 1, 2025
621.10 M JPY
Jan 1, 2026
548.04 M JPY
The TMS Co R&D Expenses history
YEARR&D ExpensesYoY
548.04 MJPY-11.76%
621.10 MJPY+2.20%
607.73 MJPY+107.59%
292.76 MJPY+183.93%
103.11 MJPY-82.91%
603.24 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Research & Development Expenses of TMS Co is 548.04 M JPY in 2026.

Research & Development Expenses of TMS Co changed from 621.10 M JPY to 548.04 M JPY, representing a -11.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses TMS Co since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — TMS Co

All Key Metrics — TMS Co